loading page

Clinical evaluation of late outcomes in Dutch childhood cancer survivors: methodology of the DCCSS LATER study part 2
  • +20
  • Elizabeth A.M. Feijen,
  • Jop Teepen,
  • Eline van Dulmen-den Broeder,
  • Marry Van den Heuvel-Eibrink,
  • Margriet van der Heiden,
  • Helena van der Pal,
  • Andrica de Vries,
  • Marloes Louwerens,
  • Dorine Bresters,
  • A Versluys,
  • Hanneke de Ridder-Sluiter,
  • Margreet Veening,
  • Flora van Leuuwen,
  • Martha A. Grootenhuis,
  • Heleen Maurice-Stam,
  • Hanneke Santen,
  • Sebastian Neggers,
  • Saskia Pluijm,
  • Jaap Den Hartogh,
  • Cecile Ronckers,
  • Wim Tissing,
  • Jacqueline Loonen,
  • Leontien Kremer
Elizabeth A.M. Feijen
Princess Maxima Center for Pediatric Oncology

Corresponding Author:[email protected]

Author Profile
Jop Teepen
Princess Máxima Center for Pediatric Oncology
Author Profile
Eline van Dulmen-den Broeder
Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Paediatrics,
Author Profile
Marry Van den Heuvel-Eibrink
Erasmus MC Sophia Children
Author Profile
Margriet van der Heiden
Princess Maxima Center for Pediatric Oncology
Author Profile
Helena van der Pal
Princess Máxima Center for Pediatric Oncology
Author Profile
Andrica de Vries
Erasmus MC – Sophia Children’s Hospital
Author Profile
Marloes Louwerens
Leiden University Medical Center
Author Profile
Dorine Bresters
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Author Profile
A Versluys
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
Author Profile
Hanneke de Ridder-Sluiter
Princess Máxima Center for pediatric oncology
Author Profile
Margreet Veening
Prinses Maxima Centrum voor Kinderoncologie
Author Profile
Flora van Leuuwen
Netherlands Cancer Institute
Author Profile
Martha A. Grootenhuis
Princess Máxima Center for Pediatric Oncology
Author Profile
Heleen Maurice-Stam
Princess Máxima Center for pediatric oncology
Author Profile
Hanneke Santen
Wilhelmina Children's Hospital
Author Profile
Sebastian Neggers
erasmus University Medical Center
Author Profile
Saskia Pluijm
Prinses Maxima Centrum
Author Profile
Jaap Den Hartogh
Vereniging Kinderkanker Nederland
Author Profile
Cecile Ronckers
Prinses Maxima Centrum voor Kinderoncologie
Author Profile
Wim Tissing
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Author Profile
Jacqueline Loonen
Radboud university medical center, Amalia Children’s Hospital
Author Profile
Leontien Kremer
Princess Máxima Center for Pediatric Oncology
Author Profile

Abstract

Background Childhood cancer survivors face late health problems; despite advances in research, details on risk remain unclear. We describe the methodological aspects of the Dutch Childhood Cancer Survivor Study (DCCSS) cross-sectional clinical study (LATER 2 study). Procedure From the multi-center DCCSS LATER cohort of 6,165 five-year survivors diagnosed 1963-2001, we invited 4,735 eligible in 2016, as well as siblings and parents of survivors. Gaps in evidence identified during development of surveillance guidelines were translated into clinical research questions for 16 outcome-specific sub-projects. The regular care visit to the LATER outpatient clinic forms the backbone of outcome assessment complemented with research-defined measurements (physical examination, diagnostic tests, questionnaires). Furthermore, blood/saliva samples were taken for DNA extraction. Results In total, 2519 (53.2%) survivors participated in the LATER 2 study. Of those participating survivors, 49.3% was female. Median time since childhood cancer diagnosis was 26.9 years (range 14.8 to 54.7 years) and median attained age was 34.4 years (range 15.4 to 66.6 years). Conclusions The high-quality data generated in the LATER 2 study will provide valuable insights into risks of and risk factors for clinical and (psychosocial) health outcomes and factors for early recognition of (psychosocial) health outcomes in long-term childhood cancer survivors. This will contribute to fill in important gaps in knowledge and improve the quality of life and care for childhood cancer survivors.
12 May 2022Assigned to Editor
12 May 2022Submitted to Pediatric Blood & Cancer
12 May 2022Submission Checks Completed
28 May 2022Reviewer(s) Assigned
19 Jun 2022Review(s) Completed, Editorial Evaluation Pending
22 Jun 2022Editorial Decision: Revise Major
19 Oct 2022Assigned to Editor
19 Oct 20221st Revision Received
19 Oct 2022Submission Checks Completed
20 Oct 2022Review(s) Completed, Editorial Evaluation Pending
20 Oct 2022Reviewer(s) Assigned
29 Oct 2022Editorial Decision: Revise Minor
28 Dec 2022Submission Checks Completed
28 Dec 2022Assigned to Editor
28 Dec 20222nd Revision Received
29 Dec 2022Review(s) Completed, Editorial Evaluation Pending
29 Dec 2022Editorial Decision: Accept